Storyboard

Why the FDA's Approval of Biogen's Alzheimer's Drug is So Controversial

The first treatment against Alzheimer's Disease in nearly 20 years received the Food and Drug Administration's approval on Monday. However, the agency's decision is being scrutinized after an independent panel of experts declined to endorse the drug from Biogen pharmaceuticals. Scientists questioned the data from its clinical trials, saying it wasn't conclusive enough. And Biogen isn't the only drug maker with suspect data either.

Why the FDA's Approval of Biogen's Alzheimer's Drug is So Controversial

Photo: ic-cdn.flipboard.com

Continue to read
11 stories in this Storyboard

Related articles

More stories from Medicine

More stories from Scientific Research